الفهرس 
AcknowledgementOnly 14 pages are availabe for public view
 |  | from | 74 |  |  |
| | | from | 74 | | |
Abstract
In this prospective study, conducted in 100 patients be recruited from, El-Rajhy University Hospital from January 2016 till January 2017.
One hundred patients with HCV infection was selected according the selection criteria determined by the National Committee for Control of Viral Hepatitis (NCCVH). Follow up HCV RNA quantitation will be done at intervals: after week 4, week 12, week 24 (from the start of therapy).
Those with chronic hepatitis (CH) and included 75 patients received dual therapy for three months and those with liver cirrhosis (LC) and included 25 patients received dual therapy for six month.
All patients received this dual therapy (Sofosbuvir 400 mg plus Daclatasvir 60 mg) for 12 weeks or 24 weeks according to EASL guidelines for chronic hepatitis C, and liver cirrhosis respectively. All of them were naïve.
Follow up HCV RNA quantitation was done at intervals: after week 4, week 12, week 24 (from the start of therapy). HCV RNA was negative in98/100 patients (98%) from the 4th week of treatment 98 patients (98%) at the end of treatment and 98 patients (98%) after 3 months post- treatment.
Only two patients failed to achieve SVR; one patient had chronic hepatitis, but takes irregular course of therapy while the other was cirrhotic patient.
Conclusion :
This regimen of therapy has high success ratio for viral eradication with minimal tolerable side effects.
Recommendations
Based on current study, we recommended;
Screening of HCV infection and early treatment before occurrence of complications of the disease.
These regimen of therapy has a great margin of safety with high efficacy
One of the main limitations of our current study was absence of frequent follow up and monitoring every 3 months to determine sustained virological response and for treatment of the relapsing cases after the end of treatment by 3 times and we recommended this to assess the o